Related Experiment Video
Updated: May 10, 2025
The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers
Published on: January 22, 2013
Unraveling the Therapeutic Potential of Scutellarin for Clear Cell Renal Cell Carcinoma: A Comprehensive Molecular
Yangyang Bai1,2, Yilin Guo3, Ruiting Chen2
1Department of Urology, Tianjin Medical University General Hospital, Tianjin Medical University, Tianjin, 300052, China.
Background:
Clear cell renal cell carcinoma (ccRCC), the most common subtype of renal cell carcinoma, is a significant global health issue. Despite advancements in surgery and systemic therapies, drug resistance remains a challenge, and more effective treatments are needed. Scutellarin, a natural flavonoid with anticancer properties, is a promising therapeutic option for ccRCC.
Methods:
This present study identified the potential target genes of scutellarin by searching four databases and utilized the TCGA-KIRC and GSE53757 datasets to identify ccRCC features genes. Protein-protein interaction networks and molecular complex detection analyses determined the hub genes through which scutellarin acts on ccRCC. Differential expression, receiver operating characteristic analysis, survival, and immune cell infiltration analyses were conducted successively on these hub genes in tumor and normal tissues to verify their clinical significance. The intracellular mechanism of the hub genes was explored using a single-cell dataset (GSE222703) to elucidate the intracellular pathway through which scutellarin exerts its anti-ccRCC effects. At last, molecular docking and molecular dynamics simulations were performed to confirm the stability of the receptor protein of the hub gene binding to scutellarin.
Results:
158 scutellarin targets were collected and identified through database searches. Analyzing the TCGA-KIRC and GSE53757 datasets separately identified finally 132 ccRCC feature genes through differential expression analysis and WGCNA. Protein-protein interaction network and molecular complex detection analyses revealed 26 hub genes potentially involved in key pathways of scutellarin in ccRCC. Differential expression analysis revealed significant differences in the expression of these hub genes between tumor and normal tissues. Receiver operating characteristic analysis demonstrated the fine diagnostic efficacy of these hub genes. Survival analysis indicated that the hub genes TYMS and CDCA2 were associated with a better prognosis, whereas the remaining hub genes had a poorer prognosis. Enrichment analysis revealed that hub genes mainly involved oxidative stress and cell cycle regulation. Single-cell RNA sequencing analysis suggested that most hub genes exert their effects on T helper cells. Molecular docking results showed stable docking of hub genes with scutellarin, except for SPAG5 and ASPM. Molecular dynamics simulations of the most stable docking sites, KIF20A, TYMS, and KIF18B, indicated stable complex formation compared with that of the internal reference protein GAPDH.
Conclusion:
This integrated study provides a comprehensive analysis of the molecular targets and pathways affected by scutellarin in ccRCC. The identified hub genes and their related pathways present exciting prospects for therapeutic intervention and highlight the potential of scutellarin as a novel treatment for ccRCC. Additional research is necessary to investigate the precise molecular mechanisms and therapeutic advantages of scutellarin in preclinical and clinical contexts.
Insights
Scutellarin shows promise as a novel treatment for clear cell renal cell carcinoma (ccRCC). This study identified key genes and pathways, revealing its potential to combat drug resistance in ccRCC.
Area of Science:
- Oncology
- Pharmacology
- Bioinformatics
Background:
- Clear cell renal cell carcinoma (ccRCC) presents a significant global health challenge, with drug resistance limiting current treatment efficacy.
- Scutellarin, a natural flavonoid, exhibits anticancer properties and is being explored as a potential therapeutic agent for ccRCC.
Purpose of the Study:
- To identify the molecular targets and pathways of scutellarin in ccRCC.
- To explore the therapeutic potential of scutellarin for ccRCC treatment.
Main Methods:
- Utilized bioinformatics databases and datasets (TCGA-KIRC, GSE53757) to identify ccRCC feature genes and scutellarin targets.
- Employed protein-protein interaction networks and molecular complex detection to identify hub genes.
- Conducted differential expression, ROC, survival, and immune cell infiltration analyses, along with single-cell RNA sequencing and molecular docking simulations.
Main Results:
- Identified 158 scutellarin targets and 132 ccRCC feature genes, revealing 26 hub genes.
- Hub genes TYMS and CDCA2 were associated with better prognosis, while others indicated poorer outcomes.
- Enrichment analysis linked hub genes to oxidative stress and cell cycle regulation, with effects on T helper cells; molecular docking confirmed stable binding of scutellarin to key hub genes like KIF20A, TYMS, and KIF18B.
Conclusions:
- This study provides a comprehensive molecular understanding of scutellarin's action in ccRCC.
- The identified hub genes and pathways offer potential therapeutic targets for ccRCC.
- Scutellarin demonstrates promise as a novel treatment for ccRCC, warranting further preclinical and clinical investigation.
More Related Videos
06:38A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
Published on: April 12, 2017
05:36Comparing Metastatic Clear Cell Renal Cell Carcinoma Model Established in Mouse Kidney and on Chicken Chorioallantoic Membrane
Published on: February 8, 2020